Drug and Alcohol Rehabilitation: Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib.
Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib.
Filed under: Drug and Alcohol Rehabilitation
PLoS One. 2013; 8(1): e53263
Gelman JS, Sironi J, Berezniuk I, Dasgupta S, Castro LM, Gozzo FC, Ferro ES, Fricker LD
Bortezomib is an antitumor drug that competitively inhibits proteasome beta-1 and beta-5 subunits. While the impact of bortezomib on protein stability is known, the effect of this drug on intracellular peptides has not been previously explored. A quantitative peptidomics technique was used to examine the effect of treating human embryonic kidney 293T (HEK293T) cells with 5-500 nM bortezomib for various lengths of time (30 minutes to 16 hours), and human neuroblastoma SH-SY5Y cells with 500 nM bortezomib for 1 hour. Although bortezomib treatment decreased the levels of some intracellular peptides, the majority of peptides were increased by 50-500 nM bortezomib. Peptides requiring cleavage at acidic and hydrophobic sites, which involve beta-1 and -5 proteasome subunits, were among those elevated by bortezomib. In contrast, the proteasome inhibitor epoxomicin caused a decrease in the levels of many of these peptides. Although bortezomib can induce autophagy under certain conditions, the rapid bortezomib-mediated increase in peptide levels did not correlate with the induction of autophagy. Taken together, the present data indicate that bortezomib alters the balance of intracellular peptides, which may contribute to the biological effects of this drug.
HubMed – drug
Identification of the Molecular Site of Ivabradine Binding to HCN4 Channels.
Filed under: Drug and Alcohol Rehabilitation
PLoS One. 2013; 8(1): e53132
Bucchi A, Baruscotti M, Nardini M, Barbuti A, Micheloni S, Bolognesi M, Difrancesco D
Ivabradine is a specific heart rate-reducing agent approved as a treatment of chronic stable angina. Its mode of action involves a selective and specific block of HCN channels, the molecular components of sinoatrial “funny” (f)-channels. Different studies suggest that the binding site of ivabradine is located in the inner vestibule of HCN channels, but the molecular details of ivabradine binding are unknown. We thus sought to investigate by mutagenesis and in silico analysis which residues of the HCN4 channel, the HCN isoform expressed in the sinoatrial node, are involved in the binding of ivabradine. Using homology modeling, we verified the presence of an inner cavity below the channel pore and identified residues lining the cavity; these residues were replaced with alanine (or valine) either alone or in combination, and WT and mutant channels were expressed in HEK293 cells. Comparison of the block efficiency of mutant vs WT channels, measured by patch-clamp, revealed that residues Y506, F509 and I510 are involved in ivabradine binding. For each mutant channel, docking simulations correctly explain the reduced block efficiency in terms of proportionally reduced affinity for ivabradine binding. In summary our study shows that ivabradine occupies a cavity below the channel pore, and identifies specific residues facing this cavity that interact and stabilize the ivabradine molecule. This study provides an interpretation of known properties of f/HCN4 channel block by ivabradine such as the “open channel block”, the current-dependence of block and the property of “trapping” of drug molecules in the closed configuration.
HubMed – drug
Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study.
Filed under: Drug and Alcohol Rehabilitation
PLoS One. 2013; 8(1): e53078
Buron F, Malvezzi P, Villar E, Chauvet C, Janbon B, Denis L, Brunet M, Daoud S, Cahen R, Pouteil-Noble C, Gagnieu MC, Bienvenu J, Bayle F, Morelon E, Thaunat O
The use of the immunosuppressant sirolimus in kidney transplantation has been made problematic by the frequent occurrence of various side effects, including paradoxical inflammatory manifestations, the pathophysiology of which has remained elusive.30 kidney transplant recipients that required a switch from calcineurin inhibitor to sirolimus-based immunosuppression, were prospectively followed for 3 months. Inflammatory symptoms were quantified by the patients using visual analogue scales and serum samples were collected before, 15, 30, and 90 days after the switch.66% of patients reported at least 1 inflammatory symptom, cutaneo-mucosal manifestations being the most frequent. Inflammatory symptoms were characterized by their lability and stochastic nature, each patient exhibiting a unique clinical presentation. The biochemical profile was more uniform with a drop of hemoglobin and a concomitant rise of inflammatory acute phase proteins, which peaked in the serum 1 month after the switch. Analyzing the impact of sirolimus introduction on cytokine microenvironment, we observed an increase of IL6 and TNF? without compensation of the negative feedback loops dependent on IL10 and soluble TNF receptors. IL6 and TNF? changes correlated with the intensity of biochemical and clinical inflammatory manifestations in a linear regression model.Sirolimus triggers a destabilization of the inflammatory cytokine balance in transplanted patients that promotes a paradoxical inflammatory response with mild stochastic clinical symptoms in the weeks following drug introduction. This pathophysiologic mechanism unifies the various individual inflammatory side effects recurrently reported with sirolimus suggesting that they should be considered as a single syndromic entity.
HubMed – drug
Indianapolis Indiana Alcoholism Rehabs – www.transformationstreatment.com Transformations, provides other services including a relapse prevention and drug and alcohol aftercare program, which are scheduled many times per week. If a person is having issues or going through a moment of weakness after drug and alcohol rehabilitation has concluded, having these services is vital to maintaining ongoing recovery. After completing a 90-day program and following the aftercare treatment program, a person is eligible to receive an additional 28-day treatment program at no additional cost if the need such as a relapse arises. Transformations Treatment Center takes the care and recovery of our clients very seriously and will do whatever is necessary to help a person stay focused and dedicated to lifelong sobriety. For More Information Give us a Call, 1-866-211-5538.
More Drug And Alcohol Rehabilitation Information…